<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04626700</url>
  </required_header>
  <id_info>
    <org_study_id>201802177A3</org_study_id>
    <nct_id>NCT04626700</nct_id>
  </id_info>
  <brief_title>Comparison for Oral Negative Pressure Therapy and CPAP for OSA Under Sleep Endoscopy Assistance: A Randomized Controlled Trial</brief_title>
  <official_title>Thoracic Department, Chang Gung Memorial Hospital, Linko Main Branch</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the study entitled &quot;Comparison for oral negative pressure therapy and CPAP for OSA&#xD;
      under sleep endoscopy assistance: A randomized controlled trial&quot;. CPAP is first line golden&#xD;
      standard treatment for Obstructive sleep apnea (OSA). However, the overall CPAP compliance is&#xD;
      poor. Recent study reveals that oral negative pressure therapy improves apnea severity in OSA&#xD;
      patients with good compliance. However, no study is designed to compare oral negative&#xD;
      pressure therapy and CPAP for OSA patients. In addition, the effect of oral negative pressure&#xD;
      therapy for hypopharynx is unclear. Therefore, we will perform druginduced sleep endoscopy to&#xD;
      evaluate upper airway obstruction of OSA patients before treatment. OSA patients will be&#xD;
      assigned into oral negative pressure group or CPAP group for 2 months. Sleepiness, sleep&#xD;
      quality, residual apnea severity and compliance will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Epworth Sleepiness Scale (ESS)</measure>
    <time_frame>Change from Baseline ESS at 1 month</time_frame>
    <description>lower ESS means better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Epworth Sleepiness Scale (ESS)</measure>
    <time_frame>Change from Baseline ESS at 2 months</time_frame>
    <description>lower ESS means better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>apnea-hypopnea index (AHI)</measure>
    <time_frame>Change from Baseline AHI at 2 months</time_frame>
    <description>lower AHI means better outcome</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>OSA</condition>
  <condition>iNAP</condition>
  <condition>DISE</condition>
  <arm_group>
    <arm_group_label>iNAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iNAP</intervention_name>
    <description>iNAP for the treatment of OSA</description>
    <arm_group_label>iNAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP</intervention_name>
    <description>CPAP for the treatment of OSA</description>
    <arm_group_label>CPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  mild to moderate OSA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hypopharynx obstruction&#xD;
&#xD;
          -  ASA classification of physical status)&gt;3&#xD;
&#xD;
          -  allergy toDexmedetomidine&#xD;
&#xD;
          -  COPD stage IV&#xD;
&#xD;
          -  Asthma with exacerbation&#xD;
&#xD;
          -  severe CHF&#xD;
&#xD;
          -  age &lt; 18 year-old&#xD;
&#xD;
          -  claustraphobia&#xD;
&#xD;
          -  any reason : can not tolerate CPAP&#xD;
&#xD;
          -  second or third degree AVB&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsang-Tang Hsieh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institutional Review Board Chang Gung Medical Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tsai-Yu Wang, MD</last_name>
    <phone>+886975368076</phone>
    <email>wang5531@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Thoracic Medicine, Chang Gung Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>105</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TSAI-YU WANG, MD</last_name>
      <phone>886-03-3281200</phone>
      <phone_ext>8467</phone_ext>
      <email>wang5531@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 1, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

